Article ID Journal Published Year Pages File Type
8445377 European Journal of Cancer 2013 7 Pages PDF
Abstract
The discontinuation rate in the TAM group was high, and the discontinuations also occurred early. Even though there were significantly more non-serious gynaecological events during the TAM treatment, routine gynaecological follow-up cannot be recommended.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Preview
A double-blind placebo-controlled study to evaluate endometrial safety and gynaecological symptoms in women treated for up to 5 years with tamoxifen or placebo - A substudy for IBIS I Breast Cancer Prevention Trial
Authors
, , , , , ,